基于双向孟德尔随机化的不同BMI分型非酒精性脂肪性肝病与2型糖尿病的遗传关联分析

段浩鑫; 江宇泳; 吴亭彧; 熊飞翔; 姜艳丹; 张琴; 赵赛赛; 于浩

doi:10.12449/JCH241011

基于双向孟德尔随机化的不同BMI分型非酒精性脂肪性肝病与2型糖尿病的遗传关联分析

DOI: 10.12449/JCH241011

段浩鑫^{1, 2},
江宇泳²,
吴亭彧¹,
熊飞翔¹,
姜艳丹¹,
张琴¹,
赵赛赛¹,
于浩^2, , ,

1.
北京中医药大学东直门医院研究生院，北京 100700
2.
首都医科大学附属北京地坛医院中西医结合中心，北京 100015

基金项目:

北京市高层次公共卫生技术人才建设项目培养计划 (Discipline Leader-03-04);

首都卫生科研发展专项基金 (2020-2-2172)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：段浩鑫负责文章设计，数据处理与分析，论文撰写；江宇泳、于浩负责思路指正，写作指导和文章修改；吴亭彧、熊飞翔负责数据处理与分析；姜艳丹、张琴、赵赛赛负责文献检索，数据搜集。

详细信息

通信作者:
于浩， yuhaodtyy@126.com （ORCID： 0000-0002-2213-0725）

计量
- 文章访问数: 16
- HTML全文浏览量: 11
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2024-06-04
- 录用日期: 2024-07-25
- 出版日期: 2024-10-25

The genetic association between nonalcoholic fatty liver disease and type 2 diabetes mellitus in different body mass index categories： A bidirectional Mendelian randomization study

1.
Graduate School，Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 100700，China
2.
Department of Integrative Medicine，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

Beijing Municipal High Rank Public Health Researcher Training Program (Discipline Leader-03-04);

Capital Health Research and Development Project (2020-2-2172)

More Information

Corresponding author: YU Hao， yuhaodtyy@126.com （ORCID： 0000-0002-2213-0725）

摘要

摘要: 目的运用双向双样本孟德尔随机化（MR）评估非酒精性脂肪性肝病（NAFLD）与2型糖尿病（T2DM）的遗传关联，并进一步探讨不同BMI的NAFLD人群与T2DM的因果关系。方法数据来源于以欧洲人群为研究对象的全基因组关联研究，其中NAFLD的样本量为32 941例，T2DM为312 646例，BMI为681 275例。运用单变量、多变量MR方法评估NAFLD总人群及各BMI亚型与T2DM之间的双向因果关系。采用逆方差加权法、MR-Egger回归、约束最大似然与模型平均法、加权中位数法进行MR分析，采用MR多效性残差和与离群值、径向MR、MR-Egger截距法、Cochran Q检验进行敏感性分析。结果单变量MR分析显示NAFLD总人群与T2DM之间存在双向因果关系（正向OR=9.75，95%CI：2.57～37.00，P<0.001；反向OR=1.01，95%CI：1.00～1.01，P<0.01）。多变量MR分析显示经BMI校正后，NAFLD总人群与T2DM的因果关系仍然保持显著（OR=33.12，95%CI：7.57～144.95，P<0.000 1）。亚组分析显示，NAFLD各亚组均与T2DM存在因果关系（瘦型OR=12.19，95%CI：3.35～44.40，P<0.001；超重型OR=4.30，95%CI：1.69～10.92，P<0.01；肥胖型OR=1.67，95%CI：1.14～2.44，P<0.01）。结论本研究从遗传学层面揭示了NAFLD总人群及各BMI亚型与T2DM之间的因果关系。
- 非酒精性脂肪性肝病 /
- 糖尿病， 2型 /
- 身体质量指数 /
- 孟德尔随机化分析
Abstract: Objective To investigate the genetic association between nonalcoholic fatty liver disease （NAFLD） and type 2 diabetes mellitus （T2DM） using bidirectional two-sample Mendelian randomization （MR）， as well as the causal relationship between NAFLD and T2DM across different body mass index （BMI） categories. Methods The data were derived from genome-wide association studies conducted in European populations， with a sample size of 32 941 cases for NAFLD， 312 646 cases for T2DM， and 681 275 cases for BMI. The univariate and multivariate MR methods were used to assess the bidirectional causal relationship between NAFLD and T2DM in the general population and across different BMI subtypes. The methods of inverse-variance weighting， MR-Egger regression， constrained maximum likelihood and model averaging， and weighted median were used to conduct the MR analysis， and MR-Pleiotropy Residual Sum and Outlier， radial MR， the MR-Egger intercept method， and the Cochrane Q test were used for sensitivity analysis. Results The univariate MR analysis revealed a bidirectional causal relationship between NAFLD and T2DM in the general population （forward analysis： odds ratio ［OR］=9.75， 95% confidence interval ［CI］： 2.57‍ ‍—‍ ‍37.00， P<0.001； reverse analysis： OR=1.01， 95%CI： 1.00‍ ‍—‍ ‍1.01， P<0.01）. After adjustment for BMI， the multivariate MR analysis showed that the causal relationship between NAFLD and T2DM remained significant in the general population （OR=33.12， 95%CI： 7.57‍ ‍—‍ ‍144.95， P<0.000 1）. The subgroup analysis showed a causal relationship between NAFLD and T2DM across all BMI subtypes （lean subgroup： OR=12.19， 95%CI： 3.35‍ ‍—‍ ‍44.40， P<0.001； overweight subgroup： OR=4.30， 95%CI： 1.69‍ ‍—‍ ‍10.92， P<0.01； obese subgroup： OR=1.67， 95%CI： 1.14‍ ‍—‍ ‍2.44， P<0.01）. Conclusion This study reveals the causal relationship between NAFLD and T2DM in the general population of NAFLD and across different BMI subtypes from a genetic perspective.
- Non-alcoholic Fatty Liver Disease /
- Diabetes Mellitus， Type 2 /
- Body Mass Index /
- Mendelian Randomization Analysis

HTML全文

图 1 研究流程图

注： IVW，逆方差加权法；cML-MA，约束最大似然与模型平均法；WM，加权中位数法；MR-PRESSO，MR多效性残差和与离群值检验。

Figure 1. Study flowchart

下载: 全尺寸图片幻灯片

图 2 NAFLD总人群与T2DM的双向单变量MR结果

Figure 2. Bidirectional univariate MR results of NAFLD and T2DM in the overall population

下载: 全尺寸图片幻灯片

图 3 经BMI调整后的多变量MR分析结果

Figure 3. Multivariate MR analysis results adjusted for BMI

下载: 全尺寸图片幻灯片

图 4 NAFLD亚组与T2DM的双向单变量MR结果

Figure 4. Bidirectional univariate MR results of NAFLD subgroups and T2DM

下载: 全尺寸图片幻灯片

图 5 Leave-one-out检验结果

Figure 5. Leave-one-out test results

下载: 全尺寸图片幻灯片

表 1 各表型GWAS数据汇总信息

Table 1. Summary information of GWAS data for each phenotype

表型	数据来源	PMID	样本量（例）	种族
NAFLD（总人群）	UKB	37235137	32 941	欧洲
瘦型NAFLD	UKB	37235137	13 614	欧洲
超重型NAFLD	UKB	37235137	13 710	欧洲
肥胖型NAFLD	UKB	37235137	5 617	欧洲
T2DM	CMDKP	34862199	312 646	欧洲
BMI	GIANT	30124842	681 275	欧洲
注：PMID，PubMed唯一标识码。

下载: 导出CSV

表 2 NAFLD各组与T2DM的敏感性分析

Table 2. Sensitivity analysis of NAFLD subgroups and T2DM

暴露	结局	正向				反向
		异质性（P值）	水平多效性			异质性（P值）	水平多效性
		异质性（P值）	MR-Egger截距法P值	MR-PRESSO P值	MR-PRESSO 剔除SNP	异质性（P值）	MR-Egger截距法P值	MR-PRESSO P值	MR-PRESSO 剔除SNP
NAFLD总人群	T2DM	0.02	0.69	0.32	无	0.41	0.91	0.38	无
瘦型NAFLD	T2DM	0.98	0.05	0.71	rs17547923， rs58489806^1）	0.99	0.30	0.99	无
超重型NAFLD	T2DM	0.04	0.39	0.21	无	0.61	0.40	0.58	无
肥胖型NAFLD	T2DM	0.74	0.32	0.60	无	1.00	0.87	1.00	无
注：1）第一次MR-Egger截距法P=0.002，进一步采用径向MR剔除的SNP离群值。

下载: 导出CSV

参考文献(49)

[1]	POWELL EE, WONG VWS, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397( 10290): 2212- 2224. DOI: 10.1016/S0140-6736(20)32511-3.
[2]	RIAZI K, AZHARI H, CHARETTE JH, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 851- 861. DOI: 10.1016/S2468-1253(22)00165-0.
[3]	LI L, LIU DW, YAN HY, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies[J]. Obes Rev, 2016, 17( 6): 510- 519. DOI: 10.1111/obr.12407.
[4]	NABI O, LAPIDUS N, BOURSIER J, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes(NASH-CO Study)[J]. Hepatology, 2023, 78( 1): 272- 283. DOI: 10.1097/HEP.0000000000000329.
[5]	XU R, PAN J, ZHOU W, et al. Recent advances in lean NAFLD[J]. Biomed Pharmacother, 2022, 153: 113331. DOI: 10.1016/j.biopha.2022.113331.
[6]	TANG A, NG CH, PHANG PH, et al. Comparative burden of metabolic dysfunction in lean NAFLD vs non-lean NAFLD-A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2023, 21( 7): 1750- 1760. e 12. DOI: 10.1016/j.cgh.2022.06.029.
[7]	International Diabetes Federation. IDF Diabetes Atlas(10th ed)[M]. Brussels: International Diabetes Federation, 2022.
[8]	YOUNOSSI ZM, GOLABI P, PRICE JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes[J]. Clin Gastroenterol Hepatol, 2024. DOI: 10.1016/j.cgh.2024.03.006.[ Online ahead of print]
[9]	CAO LM, AN Y, LIU HY, et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: A systematic review and meta-analysis[J]. BMC Med, 2024, 22( 1): 101. DOI: 10.1186/s12916-024-03315-0.
[10]	GAO YT, ZHAO TY, SONG SN, et al. Lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: A literature review and meta-analysis[J]. Diabetes Res Clin Pract, 2023, 200: 110699. DOI: 10.1016/j.diabres.2023.110699.
[11]	BYRNE CD, TARGHER G. NAFLD: A multisystem disease[J]. J Hepatol, 2015, 62( 1 suppl): S47- S64. DOI: 10.1016/j.jhep.2014.12.012.
[12]	SEKULA P, FABIOLA GRECO M, PATTARO C, et al. Mendelian randomization as an approach to assess causality using observational data[J]. J Am Soc Nephrol, 2016, 27( 11): 3253- 3265. DOI: 10.1681/ASN.2016010098.
[13]	FERENCE BA, HOLMES MV, SMITH GD. Using Mendelian randomization to improve the design of randomized trials[J]. Cold Spring Harb Perspect Med, 2021, 11( 7): a040980. DOI: 10.1101/cshperspect.a040980.
[14]	SKRIVANKOVA VW, RICHMOND RC, WOOLF BAR, et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: The STROBE-MR statement[J]. JAMA, 2021, 326( 16): 1614- 1621. DOI: 10.1001/jama.2021.18236.
[15]	SUN ZW, PAN XC, TIAN AW, et al. Genetic variants in HFE are associated with non-alcoholic fatty liver disease in lean individuals[J]. JHEP Rep, 2023, 5( 7): 100744. DOI: 10.1016/j.jhepr.2023.100744.
[16]	O’CONNOR MJ, SCHROEDER P, HUERTA-CHAGOYA A, et al. Recessive genome-wide meta-analysis illuminates genetic architecture of type 2 diabetes[J]. Diabetes, 2022, 71( 3): 554- 565. DOI: 10.2337/db21-0545.
[17]	YENGO L, SIDORENKO J, KEMPER KE, et al. Meta-analysis of genome-wide association studies for height and body mass index in ∼700000 individuals of European ancestry[J]. Hum Mol Genet, 2018, 27( 20): 3641- 3649. DOI: 10.1093/hmg/ddy271.
[18]	HEMANI G, TILLING K, DAVEY SMITH G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data[J]. PLoS Genet, 2017, 13( 11): e1007081. DOI: 10.1371/journal.pgen.1007081.
[19]	BURGESS S, SCOTT RA, TIMPSON NJ, et al. Using published data in Mendelian randomization: A blueprint for efficient identification of causal risk factors[J]. Eur J Epidemiol, 2015, 30( 7): 543- 552. DOI: 10.1007/s10654-015-0011-z.
[20]	BOWDEN J, DAVEY SMITH G, BURGESS S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression[J]. Int J Epidemiol, 2015, 44( 2): 512- 525. DOI: 10.1093/ije/dyv080.
[21]	XUE HR, SHEN XT, PAN W. Constrained maximum likelihood-based Mendelian randomization robust to both correlated and uncorrelated pleiotropic effects[J]. Am J Hum Genet, 2021, 108( 7): 1251- 1269. DOI: 10.1016/j.ajhg.2021.05.014.
[22]	BOWDEN J, DAVEY SMITH G, HAYCOCK PC, et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted Median estimator[J]. Genet Epidemiol, 2016, 40( 4): 304- 314. DOI: 10.1002/gepi.21965.
[23]	SANDERSON E, DAVEY SMITH G, WINDMEIJER F, et al. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings[J]. Int J Epidemiol, 2019, 48( 3): 713- 727. DOI: 10.1093/ije/dyy262.
[24]	BURGESS S, THOMPSON SG. Interpreting findings from Mendelian randomization using the MR-Egger method[J]. Eur J Epidemiol, 2017, 32( 5): 377- 389. DOI: 10.1007/s10654-017-0255-x.
[25]	VERBANCK M, CHEN CY, NEALE B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases[J]. Nat Genet, 2018, 50( 5): 693- 698. DOI: 10.1038/s41588-018-0099-7.
[26]	BOWDEN J, SPILLER W, DEL GRECO M F, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression[J]. Int J Epidemiol, 2018, 47( 6): 2100. DOI: 10.1093/ije/dyy265.
[27]	BOWDEN J, DEL GRECO M F, MINELLI C, et al. Improving the accuracy of two-sample summary-data Mendelian randomization: Moving beyond the NOME assumption[J]. Int J Epidemiol, 2019, 48( 3): 728- 742. DOI: 10.1093/ije/dyy258.
[28]	BURGESS S, BOWDEN J, FALL T, et al. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants[J]. Epidemiology, 2017, 28( 1): 30- 42. DOI: 10.1097/EDE.0000000000000559.
[29]	Fatty Liver and Alcoholic Liver Disease Group, Hepatology Branch of Chinese Medical Association. Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases[J]. J Clin Hepatol, 2010, 2( 4): 43- 48. DOI: 10.3969/j.issn.1674-7380.2010.04.013. 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 临床肝胆病杂志, 2010, 26( 2): 120- 124. DOI: 10.3760/cma.j.jssn.1674-5809.2010.01.000.
[30]	LIU ZP, ZHANG Y, GRAHAM S, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping[J]. J Hepatol, 2020, 73( 2): 263- 276. DOI: 10.1016/j.jhep.2020.03.006.
[31]	NI XT, TONG C, HALENGBIEKE A, et al. Association between nonalcoholic fatty liver disease and type 2 diabetes: A bidirectional two-sample Mendelian randomization study[J]. Diabetes Res Clin Pract, 2023, 206: 110993. DOI: 10.1016/j.diabres.2023.110993.
[32]	MANTOVANI A, BYRNE CD, BONORA E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis[J]. Diabetes Care, 2018, 41( 2): 372- 382. DOI: 10.2337/dc17-1902.
[33]	MANTOVANI A, PETRACCA G, BEATRICE G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: An updated meta-analysis of 501 022 adult individuals[J]. Gut, 2021, 70( 5): 962- 969. DOI: 10.1136/gutjnl-2020-322572.
[34]	KOSMALSKI M, ŚLIWIŃSKA A, DRZEWOSKI J. Non-alcoholic fatty liver disease or type 2 diabetes mellitus-the chicken or the egg dilemma[J]. Biomedicines, 2023, 11( 4): 1097. DOI: 10.3390/biomedicines11041097.
[35]	KHAN RS, BRIL F, CUSI K, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease[J]. Hepatology, 2019, 70( 2): 711- 724. DOI: 10.1002/hep.30429.
[36]	ZHANG XY, LIU Y, WANG WL, et al. Diagnosis and evaluation of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2023, 39( 8): 1780- 1788. DOI: 10.3969/j.issn.1001-5256.2023.08.003. 张馨元, 刘宇, 王文玲, 等. 非酒精性脂肪性肝病的诊断与评估[J]. 临床肝胆病杂志, 2023, 39( 8): 1780- 1788. DOI: 10.3969/j.issn.1001-5256.2023.08.003.
[37]	ESLAM M, VALENTI L, ROMEO S. Genetics and epigenetics of NAFLD and NASH: Clinical impact[J]. J Hepatol, 2018, 68( 2): 268- 279. DOI: 10.1016/j.jhep.2017.09.003.
[38]	LIU DJ, PELOSO GM, YU HJ, et al. Exome-wide association study of plasma lipids in>300, 000 individuals[J]. Nat Genet, 2017, 49( 12): 1758- 1766. DOI: 10.1038/ng.3977.
[39]	BESSONE F, RAZORI MV, ROMA MG. Molecular pathways of nonalcoholic fatty liver disease development and progression[J]. Cell Mol Life Sci, 2019, 76( 1): 99- 128. DOI: 10.1007/s00018-018-2947-0.
[40]	MALONE JI, HANSEN BC. Does obesity cause type 2 diabetes mellitus(T2DM)? Or is it the opposite?[J]. Pediatr Diabetes, 2019, 20( 1): 5- 9. DOI: 10.1111/pedi.12787.
[41]	YE Q, ZOU BY, YEO YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5( 8): 739- 752. DOI: 10.1016/S2468-1253(20)30077-7.
[42]	PINGITORE P, ROMEO S. The role of PNPLA3 in health and disease[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019, 1864( 6): 900- 906. DOI: 10.1016/j.bbalip.2018.06.018.
[43]	ZHANG YJ, ZHOU XQ. Research advances in lean nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2023, 39( 12): 2914- 2919. DOI: 10.3969/j.issn.1001-5256.2023.12.024. 张瑜娟, 周希乔. 瘦型非酒精性脂肪性肝病的研究进展[J]. 临床肝胆病杂志, 2023, 39( 12): 2914- 2919. DOI: 10.3969/j.issn.1001-5256.2023.12.024.
[44]	SMITH GI, POLIDORI DC, YOSHINO M, et al. Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics[J]. J Clin Invest, 2020, 130( 6): 3305- 3314. DOI: 10.1172/JCI136756.
[45]	TOBARI M, HASHIMOTO E, TANIAI M, et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign[J]. J Gastroenterol Hepatol, 2019, 34( 8): 1404- 1410. DOI: 10.1111/jgh.14585.
[46]	PETTA S, CIMINNISI S, DI MARCO V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2017, 45( 4): 510- 518. DOI: 10.1111/apt.13889.
[47]	ZHOU XM, YU XY, SONG ZY. Clinical characteristics and management of lean nonalcoholic fatty liver disease[J]. Chin J Health Manag, 2024, 18( 3): 236- 240. DOI: 10.3760/cma.j.cn115624-20230803-00047. 周馨媚, 余馨妍, 宋震亚. 瘦型非酒精性脂肪性肝病的临床特点和管理[J]. 中华健康管理学杂志, 2024, 18( 3): 236- 240. DOI: 10.3760/cma.j.cn115624-20230803-00047.
[48]	LI N, XANG W, WU SL, et al. Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: A retrospective cohort study with a 2-year follow-up period[J]. Front Endocrinol, 2023, 14: 1173757. DOI: 10.3389/fendo.2023.1173757.
[49]	FRACANZANI AL, PETTA S, LOMBARDI R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity[J]. Clin Gastroenterol Hepatol, 2017, 15( 10): 1604- 1611. e 1. DOI: 10.1016/j.cgh.2017.04.045.